Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content


Hot Topics of the Day|PHGKB
Search PHGKB:

Archive

Hot Topics of the Day are picked by experts to capture the latest information and publications on public health genomics and precision health for various diseases and health topics. Sources include published scientific literature, reviews, blogs and popular press articles.

Search Archive:
35 hot topic(s) found with the query "Thyroid cancer"

Polygenic risk scores, radiation treatment exposures and subsequent cancer risk in childhood cancer survivors.
Todd M Gibson et al. Nat Med 2024 3 (Posted: Mar 12, 2024 0PM)

From the abstract: "Survivors of childhood cancer are at increased risk for subsequent cancers attributable to the late effects of radiotherapy and other treatment exposures; thus, further understanding of the impact of genetic predisposition on risk is needed. Combining genotype data for 11,220 5-year survivors from the Childhood Cancer Survivor Study and the St Jude Lifetime Cohort, we found that cancer-specific polygenic risk scores (PRSs) derived from general population, genome-wide association study, cancer loci identified survivors of European ancestry at increased risk of subsequent basal cell carcinoma (odds ratio per s.d. of the PRS: OR?=?1.37, 95% confidence interval (CI)?=?1.29–1.46), female breast cancer (OR?=?1.42, 95% CI?=?1.27–1.58), thyroid cancer (OR?=?1.48, 95% CI?=?1.31–1.67), squamous cell carcinoma (OR?=?1.20, 95% CI?=?1.00–1.44) and melanoma (OR?=?1.60, 95% CI?=?1.31–1.96) "

Prognostic Value of Preoperative Molecular Testing and Implications for Initial Surgical Management in Thyroid Nodules Harboring Suspected (Bethesda V) or Known (Bethesda VI) Papillary Thyroid Cancer.
Max A Schumm et al. JAMA Otolaryngol Head Neck Surg 2023 6 (Posted: Jul 01, 2023 9AM)

Is preoperative comprehensive molecular profiling associated with improved prognostication of Bethesda V and VI thyroid nodules with differentiated thyroid cancer, and how does it inform initial surgical treatment? In this cohort study of 105 consecutive patients with papillary thyroid cancer, those with high-risk molecular profiles at diagnosis were more likely to experience cancer persistence or recurrence and distance metastases and had worse 36-month recurrence-free survival than those with intermediate- and low-risk molecular profiles.

Thyroidectomy Outcomes in Patients Identified With RET Pathogenic Variants Through a Population Genomic Screening Program.
Pichardo Priscilla F A et al. JAMA otolaryngology-- head & neck surgery 2023 1 (Posted: Jan 11, 2023 6AM)

Does a population genomic screening program that discloses pathogenic/likely pathogenic RET variants to patients facilitate early detection of medullary thyroid carcinoma (MTC)? In this cross-sectional study of 20 patients, the rate of MTC was 60% in those who underwent thyroidectomy after RET results disclosure and did not have prior clinical evidence of disease or identification of the variant outside of population genomic screening. The majority of these patients (83%) were identified at stage I.

Evaluation of the Molecular Landscape of Pediatric Thyroid Nodules and Use of a Multigene Genomic Classifier in Children.
Gallant Jean-Nicolas et al. JAMA oncology 2022 6 (Posted: Jun 11, 2022 9AM)

Are pediatric thyroid nodules amenable to cancer prediction by genomic classification? In this retrospective study of 95 pediatric patients with thyroid nodules, surgical samples underwent next-generation sequencing and genomic classification. Testing defined the unique molecular landscape of pediatric thyroid nodules (which, as opposed to adults, comprised more frequent gene fusions and DICER1 variants) and identified a sensitivity of 96% and specificity of 78% regarding cancer detection.

Development of a Molecular Assay for Detection and Quantification of the BRAF Variation in Residual Tissue From Thyroid Nodule Fine-Needle Aspiration Biopsy Specimens
G Fu et al, JAMA Network Open, October 7,2021 (Posted: Oct 08, 2021 5AM)

This diagnostic study developed a molecular assay using digital polymerase chain reaction (dPCR) for sensitive detection and absolute quantification of BRAF V600E variation in the residual tissue from routine thyroid FNA biopsies. The dPCR testing showed better sensitivity than immunohistochemical staining and good concordance between residual tissue of FNA biopsies and matched surgical specimens.

Effectiveness of Molecular Testing Techniques for Diagnosis of Indeterminate Thyroid Nodules: A Randomized Clinical Trial.
Livhits Masha J et al. JAMA oncology 2020 Dec (Posted: Dec 11, 2020 9AM)

Efficacy of Selpercatinib in RET -Altered Thyroid Cancers.
Wirth Lori J et al. The New England journal of medicine 2020 Aug (9) 825-835 (Posted: Aug 27, 2020 7AM)

We enrolled patients with RET-mutant medullary thyroid cancer with or without previous vandetanib or cabozantinib treatment, as well as those with previously treated RET fusion-positive thyroid cancer, in a phase 1-2 trial of selpercatinib. Results show durable efficacy with mainly low-grade toxic effects in patients.

Molecular Profiling of Thyroid Nodules—Are These Findings Meaningful, or Merely Measurable?
LGT Morris, JAMA Oto Larnyg, July 30, 2020 (Posted: Jul 31, 2020 8AM)

Advances in genomic technologies have facilitated the development of sophisticated molecular diagnostic tests for thyroid nodules, in the hopes of better risk stratifying nodules with indeterminate cytopathologic diagnosis. It is unclear whether the widespread, or reflexive, use of these tests will improve outcomes for patients with thyroid nodules.

Development and validation of an individualized diagnostic signature in thyroid cancer.
Han Li-Ou et al. Cancer medicine 2018 Mar (Posted: Mar 14, 2018 10AM)

Mutational Markers and Risk Stratification in Thyroid Cancer-The Art of War Refined.
Story E Shannon et al. JAMA oncology 2016 Sep (Posted: Jun 16, 2017 9AM)

Molecular Profiling of Thyroid Nodules: Current Role for the Afirma Gene Expression Classifier on Clinical Decision Making.
Kloos Richard T et al. Molecular imaging and radionuclide therapy 2016 Jan 26(Suppl 1) 36-49 (Posted: Jan 25, 2017 10AM)

Genomic Profiling of Thyroid Nodules: Current Role for ThyroSeq Next-Generation Sequencing on Clinical Decision-Making.
Kargi Atil Y et al. Molecular imaging and radionuclide therapy 2016 Jan 26(Suppl 1) 24-35 (Posted: Jan 25, 2017 10AM)

Hereditary Thyroid Cancer: Part I
My Gene Counsel, January 24, 2017 (Posted: Jan 24, 2017 3PM)

Molecular genetics of thyroid cancer.
Reba? Maha et al. Genetics research 2016 May e7 (Posted: Jan 21, 2017 3PM)

Familial non-medullary thyroid cancer: unraveling the genetic maze.
Peiling Yang Samantha et al. Endocrine-related cancer 2016 Dec (12) R577-R595 (Posted: Jan 21, 2017 3PM)

The role of microRNAs in thyroid carcinomas.
Forte Stefano et al. Anticancer Res. 2015 Apr (4) 2037-47 (Posted: Jul 08, 2015 0PM)

Molecular Pathology of Hereditary and Sporadic Medullary Thyroid Carcinomas.
Chernock Rebecca D et al. Am. J. Clin. Pathol. 2015 Jun (6) 768-777 (Posted: Jul 08, 2015 0PM)

PI3K/Akt/mTOR: A promising therapeutic target for non-medullary thyroid carcinoma.
Petrulea Mirela S et al. Cancer Treat. Rev. 2015 Jun 26. (Posted: Jul 08, 2015 0PM)

American Thyroid Association Statement on Surgical Application of Molecular Profiling for Thyroid Nodules: Current Impact on Perioperative Decision Making.
Ferris Robert L et al. Thyroid 2015 Jun 24. (Posted: Jul 08, 2015 0PM)

Epigenetic modifications in human thyroid cancer.
Faam Bita et al. Biomed Rep 2015 Jan (1) 3-8 (Posted: Mar 29, 2015 2PM)

CHEK2 mutations and the risk of papillary thyroid cancer.
Siolek Monika et al. Int. J. Cancer 2015 Jan 12. (Posted: Mar 29, 2015 2PM)

Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy.
Schechter Rebecca B et al. Cancer Lett. 2015 Apr 10. (2) 269-74 (Posted: Mar 29, 2015 2PM)

Targeted therapy for genetic cancer syndromes: Fanconi anemia, medullary thyroid cancer, tuberous sclerosis, and RASopathies.
Agarwal Rishi et al. Discov Med 2015 Feb (103) 101-8 (Posted: Mar 29, 2015 2PM)

Consensus on the management of advanced medullary thyroid carcinoma on behalf of the Working Group of Thyroid Cancer of the Spanish Society of Endocrinology (SEEN) and the Spanish Task Force Group for Orphan and Infrequent Tumors (GETHI).
Galofré Juan C et al. Endocrinol Nutr 2015 Apr (4) e37-46 (Posted: Mar 29, 2015 2PM)

Novel genetic variants in differentiated thyroid cancer and assessment of the cumulative risk.
Figlioli Gisella et al. Sci Rep 2015 8922 (Posted: Mar 29, 2015 2PM)

Clinical significance of papillary thyroid cancer risk loci identified by genome-wide association studies.
Wei Wen-Jun et al. Cancer Genet 2015 Jan 30. (Posted: Mar 29, 2015 2PM)

Find our which genetic conditions and tests are associated with thyroid cancer
from the NIH Genetic Testing Registry Brand (Posted: Mar 29, 2015 2PM)

Risk factors for thyroid cancer include genetics and family history
from the American Cancer Society (Posted: Mar 29, 2015 2PM)

What is Thyroid Cancer
from the National Cancer Institute (Posted: Mar 29, 2015 2PM)

Thyroid Cancer—Patient Version
Brand (Posted: Jan 11, 2014 11AM)

Overview The thyroid is a gland at the base of the throat near the windpipe. It is shaped like a butterfly, with a right lobe and a left lobe. A thin piece of tissue connects the two lobes. The thyroid makes hormones that help control heart rate, blood pressure, body temperature, and weight. There are four types of thyroid cancer. These are papillary, follicular, medullary, and anaplastic thyroid cancer. Papillary is the most common type of thyroid cancer. Anaplastic thyroid cancer is hard to cure with current treatment. Other types of thyroid cancer can usually be cured. Being exposed to radiation to the head and neck as a child increases the risk of thyroid cancer. Having certain genetic conditions such as familial medullary thyroid cancer, multiple endocrine neoplasia type 2A syndrome, and multiple endocrine neoplasia type 2B syndrome can also increase the risk of thyroid cancer.

Anaplastic thyroid cancer
From NCATS Genetic and Rare Diseases Information Center Brand (Posted: Jan 01, 2011 0AM)

Thyroid cancer, follicular
From NCATS Genetic and Rare Diseases Information Center Brand (Posted: Jan 01, 2011 0AM)

Thyroid cancer, medullary
From NCATS Genetic and Rare Diseases Information Center Brand (Posted: Jan 01, 2011 0AM)

Thyroid cancer, childhood
From NCATS Genetic and Rare Diseases Information Center Brand (Posted: Jan 01, 2011 0AM)

Hurthle cell thyroid cancer
From NCATS Genetic and Rare Diseases Information Center Brand (Posted: Jan 01, 2011 0AM)


Disclaimer: Articles listed in Hot Topics of the Day are selected by Public Health Genomics Branch to provide current awareness of the scientific literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the Clips, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
TOP